Loading...
Innoviva reported an 18% year-over-year growth in royalty revenues for the fourth quarter, driven by strong performance in its core royalty business and strategic investments.
Royalty revenues grew 18% year over year.
RELVAR®/BREO® ELLIPTA® global net sales increased 3% compared to Q4 2020.
ANORO® ELLIPTA® global net sales decreased by 17% compared to Q4 2020.
TRELEGY® ELLIPTA® global net sales increased 53% compared to Q4 2020.
Analyze how earnings announcements historically affect stock price performance